NEW YORK (GenomeWeb News) – A new center in Ontario, Canada focused on pharmacogenetic applications for addiction and mental health has been established with a C$19 million (US$19.1 million) investment.

The center, called the Tanenbaum Centre for Pharmacogenetics, is a collaboration between businessman Lawrence Tanenbaum, the Ontario government, and the Centre for Addiction and Mental Health (CAMH) and will support research to accelerate the time it takes to get genetic information to physicians and patients in Ontario.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.